Clinical Trial Update: Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating whether aprepitant alters the pharmacokinetics of cyclophosphamide in patients with breast cancer; provides PK interaction data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Nausea and Vomiting

Drugs mentioned

• Aprepitant (aprepitant)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Breast Cancer, Nausea and Vomiting | Phase 1 | Status: COMPLETED